Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: Study design and data analysis issues

Journal of Clinical Pharmacology

Volumn 39, Issue 10, 1999, Pages 1006-1014

  Huang, S M ^a   Lesko, L J ^a   Williams, R L ^a  

^a Office of Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CIMETIDINE; DIGOXIN; NEW DRUG; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; TERFENADINE; THEOPHYLLINE; WARFARIN;

ARTICLE; CLINICAL TRIAL; DRUG INTERACTION; DRUG LABELING; DRUG METABOLISM; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; METHODOLOGY; QUALITY CONTROL; STATISTICAL ANALYSIS;

EID: 0033306846     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922011764     Document Type: Article

References (35)

1. Assessment of clinical pharmacology information (CPI) in drug labeling
2. Incidence of adverse drug events and potential adverse drug events: Implications for prevention
3. Torsades de pointes occurring in association with terfenadine use
4. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant adminstrations of erythromycin
5. Terfenadine-ketoconazole interactions: Pharmacokinetic and electrocardiographic consequences
6. Mechanism of the cardiotoxic actions of terfenadine
7. Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin
8. Guidance of Industry: Drug metabolism/drug interactions in the drug development process: Studies in vitro
9. Pharmacokinetic interactions between two HIV-protease inhibitors, ritonavir and saquinavir
10. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA panel
11. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
12. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus by coadministration with ritonavir
13. A survey of clinical pharmacology (CP) and biopharmaceutics (BP) studies submitted in NDAs during the period of October 1994 to September 1995
14. Mibefrradil is a potent inhibitor of both CYP3A and P-glycoprotein (P-GP)
15. From the Food and Drug Administration: Two new warnings added to labeling for mibefradil
16. What lessons can be learnt from withdrawal of mibefradil from the market?
17. Sertraline and desipramine, and imipramine
18. Life threatenting interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers
19. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid
20. Grapefruit juice has a small effect on lovastatin plasma HMG-CoA reductase inhibitor profiles
21. Confidence intervals for reporting results of clinical trials
22. Reporting of equivalence in the current medical literature: Confidence interval calculations
23. Lack of pharmacokinetic interactions as an equivalence problem
24. Lack of drug interaction between meloxicam and warfarin in healthy volunteers
25. Cyclosporine and nonsteroidal antiinflammatory drugs: Exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis
26. Guidance for industry: Pharmacokinetics in renal impairment: Study design, data analysis, and impact on dosing and labeling
27. Draft guidance for industry: In vivo metabolism/drug interactions: Study design, data analysis and recommendations for dosing and labeling
28. Guidance for industry: Population pharmacokinetics
29. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways